Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in...
Independent Report Examines Collagen Patch Benefits, Delivery Science, and What Consumers Evaluate — With Invig+ as Category ReferenceNEW YORK, NY,...
Examination of transdermal berberine delivery, GLP-1 pathway terminology in supplement marketing, and consumer evaluation criteria as searches for non-prescription metabolic...
January 2026 Wellness Season: Glutathione Tripeptide Therapy, Cellular Skin Support Mechanisms, and Telehealth Access Pathways for Injectable Peptide OptionsSHERIDAN, WY,...
DALLAS and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- M33 Growth, a Boston-based venture and growth-stage investment firm, today announced...
Together with cash on hand, the fully leveraged facility extends Aptevo's funding runway into 2029, enabling achievement of key clinical...
STAMFORD, Conn., Jan. 8, 2026 /PRNewswire/ -- Proximity Health Solutions, in collaboration with Biogen, announces that Better Together: Sharing Our Lupus...
BELFAST, Northern Ireland, Jan. 8, 2026 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on...
MINNEAPOLIS, Jan. 8, 2026 /PRNewswire/ -- Flywheel, the leading medical imaging data management and analysis platform, today announced key milestones achieved...
Combined teams and proprietary AI-technology to multiply capabilities and services as a leading provider of real-world data for clinical researchSAN...
Conference Call to be Hosted on Monday, January 12 at 1:30 PM PT/4:30 PM ET FREMONT, CA / ACCESS Newswire...
~ New ADHD pipeline leverages TAAP™ and MPAR® technologies to improve safety for patients ~ SAN DIEGO, CALIFORNIA / ACCESS...
1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of...
Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences...
Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 IBSRELA achieved $274 million in revenue...
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy...
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx’s TAMP Therapy Platform...
– Preferential MOP agonists such as oxycodone are often required for effective management of moderate to severe pain but come...
TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology...
CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of...